How Analysts Feel About AstraZeneca plc (ADR) (NYSE:AZN)?

The company has analyst rating of 1.70 on scale of 1-5. Bristol Advisors LLC's holdings in Astrazeneca PLC were worth $566,000 at the end of the most recent reporting period. The ASX listed company saw a recent bid of 0.52 and 323232 shares have traded hands in the session. Wells Fargo & Company MN increased its stake in shares of Astrazeneca PLC by 41.6% in the first quarter. First Manhattan Co. now owns 9,970 shares of the company's stock valued at $327,000 after buying an additional 370 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Astrazeneca PLC by 476.9% in the second quarter. The number of shares now owned by investors are 2.51 bln. Now we move forward to observe the past performance of AstraZeneca PLC (AZN), a United Kingdom based stock. BlackRock Inc. now owns 6,910,657 shares of the company's stock worth $215,198,000 after buying an additional 6,908,257 shares during the last quarter. It also reduced its holding in Devon Energy Corporation (NYSE:DVN) by 18,067 shares in the quarter, leaving it with 22,914 shares, and cut its stake in Microsoft Corp (NASDAQ:MSFT).

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the company's stock in a transaction that occurred on Thursday, July 27th.

Astrazeneca PLC (NYSE:AZN) traded up 0.2632% on Thursday, reaching $29.1365. The firm has a 50-day moving average price of GBX 4,902.15 and a 200-day moving average price of GBX 4,866.23. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The stock has a market capitalization of $73.77 billion, a P/E ratio of 19.1122 and a beta of 0.74. During the same quarter in the prior year, the company posted $0.83 earnings per share. The company had revenue of $5.05 billion during the quarter, compared to analysts' expectations of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm's quarterly revenue was down 9.9% on a year-over-year basis. During the same period past year, the business posted $0.83 earnings per share.

The company also recently announced a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date of this dividend is Wednesday, August 9th. The stock was acquired at an average price of GBX 4,370 ($56.73) per share, for a total transaction of £1,704.30 ($2,212.51). Astrazeneca PLC's dividend payout ratio (DPR) is 44.92%.

ILLEGAL ACTIVITY WARNING: "Bristol Advisors LLC Continues to Hold Position in Astrazeneca PLC (AZN)" was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and worldwide trademark and copyright laws. The original version of this news story can be accessed at

Several other research analysts also recently commented on AZN.

AstraZeneca plc (LON:AZN) received a GBX 4,500 ($58.42) price target from investment analysts at S&P Global in a report released on Thursday, July 27th. Barclays PLC reiterated an overweight rating on shares of Astrazeneca PLC in a research note on Monday, July 3rd. UBS downgraded the shares of AZN in report on Wednesday, April 5 to "Neutral" rating. Zacks Investment Research lowered shares of Astrazeneca PLC from a "strong-buy" rating to a "sell" rating in a research report on Monday, July 17th. Goldman Sachs Group, Inc. Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($71.40) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. 1 and 2 is equivalent to a buy rating, 3 a hold rating, and 4 and 5 a sell rating. AstraZeneca plc presently has a consensus rating of Hold and an average target price of GBX 4,932.67 ($64.04).

AstraZeneca PLC (NYSE:AZN) soared 6.44% year-to-date.